Kymera Therapeutics KYMR Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's deferred revenue?
- Kymera Therapeutics (KYMR) reported deferred revenue of $0 in Q1 2026.
- How has Kymera Therapeutics's deferred revenue changed year-over-year?
- Kymera Therapeutics's deferred revenue decreased by 100.0% year-over-year, from $11.48M to $0.
- What is the long-term trend for Kymera Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Kymera Therapeutics's deferred revenue has grown at a -24.4% compound annual growth rate (CAGR), from $92.55M to $22.93M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.